Abstract
There has been great controversy over the years regarding the impact of CYP2D6 polymorphisms on the efficacy of tamoxifen in women with breast cancer. The most significant publication to date is the 2009 publication from investigators in Stuttgart and the Mayo Clinic, a 1325 patient study published in JAMA.1 Despite this high-impact publication, there has been variable acceptance of these results due to inconsistent replication of these findings.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
